Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s dominance over the weight-loss industry. The Danish pharma giant ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...

Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling ...

Novo Nordisk's sales increased by 25% in Danish kroner (26% at constant exchange rates), reaching DKK 290.4 billion for the full year -- around $40.34 billion. Its operating profit also increased ...

Last week, Novo Nordisk released its year-end results, including how it performed over the last three months of 2024. Net sales for the quarter totaled 85.7 billion Danish kroner ($12 billion) and ...

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:NVO). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other foreign dividend stocks. Dividends have historically been a key driver of investor returns, ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...